TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX: VHIBF) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three months ended March 31, 2025 with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedarplus.com.
“We are pleased to report a strong start to 2025, achieving sequential net organic ARR⁽¹⁾ growth of $1.8 million and 26% adjusted EBITDA⁽¹⁾ in the first quarter,” said Dan Matlow, CEO of VitalHub. “We continue to strengthen our infrastructure, with improvements to process and integration capabilities. We are excited about our potential cash acquisition of UK-based Induction. Pending all approvals, we expect this acquisition to close in the third quarter of 2025 and foresee strong synergistic value.”
“We ended the first quarter with a cash balance of over $90 million. Several acquisition opportunities are moving through the pipeline, diversified in geography and scale. We continue to be selective and maintain a disciplined approach on all prospective deals. For smaller-scale opportunities, we are seeing improved pricing and considerable strategic value. We are optimistic about the pipeline for the balance of the year.”
VitalHub’s quarterly investor conference call will take place on Friday, May 9, 2025, at 9:00AM EST.
To register for the call, please visit: https://us06web.zoom.us/webinar/register/WN_dlBWXhs0S5KWdlrSakva9A#/registration
First Quarter 2025 Highlights
(1) Non-IFRS measure. Disclaimers and reconciliations can be found in SEDAR filings.
Selected Financial Information | ||||||||||
Three months ended | ||||||||||
March 31, 2025 | % Revenue | March 31, 2024 | % Revenue | Change | ||||||
$ | $ | % | ||||||||
Revenue | 21,674,966 | 100% | 15,256,791 | 100% | 42% | |||||
Cost of sales | 4,230,673 | 20% | 2,973,692 | 19% | (42%) | |||||
Gross profit | 17,444,293 | 80% | 12,283,099 | 81% | 42% | |||||
Operating expenses | ||||||||||
General and administrative | 5,270,749 | 24% | 3,191,857 | 21% | (65%) | |||||
Sales and marketing | 2,029,012 | 9% | 1,696,464 | 11% | (20%) | |||||
Research and development | 5,220,183 | 24% | 3,418,122 | 22% | (53%) | |||||
Depreciation of property and equipment | 142,077 | 1% | 77,830 | 1% | (83%) | |||||
Depreciation of right-of-use assets | 119,896 | 1% | 106,762 | 1% | (12%) | |||||
Share-based compensation | 765,400 | 4% | 348,579 | 2% | (120%) | |||||
Foreign currency (gain) | (694,407 | ) | (3%) | (68,276 | ) | (0%) | (917%) | |||
Other expenses (income) | ||||||||||
Amortization of intangible assets | 1,921,394 | 9% | 1,106,542 | 7% | (74%) | |||||
Business acquisition, restructuring and integration costs | 1,463,414 | 7% | 583,334 | 4% | (151%) | |||||
Loss on change in fair value of contingent consideration | 235,498 | 1% | 14,003 | 0% | (1582%) | |||||
Interest expense (net of interest income) | (535,309 | ) | (2%) | (184,807 | ) | (1%) | 190% | |||
Interest expense from lease liabilities | 14,903 | 0% | 13,794 | 0% | (8%) | |||||
Loss on disposal of property and equipment | 4,070 | 0% | - | 0% | (100%) | |||||
Current and deferred income taxes | 325,941 | 2% | 660,429 | 4% | (51%) | |||||
Net income | 1,161,472 | 5% | 1,318,466 | 9% | (12%) | |||||
EBITDA (Non-IFRS measure) | 3,150,374 | 15% | 3,099,016 | 20% | 2% | |||||
Adjusted EBITDA (Non-IFRS measure) | 5,614,686 | 26% | 4,044,932 | 27% | 39% | |||||
Annual recurring revenue (Non-IFRS measure) | 73,687,666 | 47,834,002 | 54% | |||||||
Term licences, maintenance and support revenue | 18,343,566 | 85% | 12,465,062 | 82% | 47% | |||||
As at | ||||||||||
March 31, 2025 | December 31, 2024 | |||||||||
$ | $ | |||||||||
Cash balance | 91,213,771 | 56,574,904 | ||||||||
Deferred revenue | 35,960,616 | 35,636,002 | ||||||||
About VitalHub
VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,000 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 500 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX: VHI) (OTCQX: VHIBF), please visit www.vitalhub.com and connect with us on LinkedIn.
Contact Information
Christian Sgro, CPA, CA, CFA
Head of IR and M&A Specialist
(365) 363-6433
This email address is being protected from spambots. You need JavaScript enabled to view it.
Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it.
Cautionary Statement
Certain statements contained in this news release may constitute "forward-looking information" or "financial outlook" within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Last Trade: | C$11.90 |
Daily Change: | 0.32 2.76 |
Daily Volume: | 196,234 |
Market Cap: | C$626.060M |
March 27, 2025 January 09, 2025 December 17, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load